Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.
Also called NCT04830449
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 122 participants
- Registry
-
NCT04830449
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04830449. Randomized; double masking; primary purpose treatment. Start 2020-10-29 (actual); primary completion 2021-08-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
- Condition
- Hypertension
- Intervention (Drug)
- HCP1904-2
- Intervention (Drug)
- RLD2001-2
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct04830449- Content hash
8936ef432d6f6b0d0f5ca6452ecdcbfd22712654226b10fb2e3d2ed38d62cb72